Chinese Journal of Cancer Research

Scope & Guideline

Shaping the future of oncology through rigorous scholarship.

Introduction

Explore the comprehensive scope of Chinese Journal of Cancer Research through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Chinese Journal of Cancer Research in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1000-9604
PublisherCHINESE JOURNAL CANCER RESEARCH CO
Support Open AccessNo
Country-
TypeJournal
Convergefrom 1988 to 1996, from 1998 to 2017 (coverage discontinued in Scopus)
AbbreviationCHINESE J CANCER RES / Chin. J. Cancer Res.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressLTD PEKING U CANCER HOSP & INST, NO 52, FUCHENG RD, HAIDIAN, BEIJING 100142, PEOPLES R CHINA

Aims and Scopes

The Chinese Journal of Cancer Research aims to advance the understanding of cancer through rigorous research, focusing on a blend of clinical and translational studies. The journal serves as a platform for disseminating significant findings that can enhance the prevention, diagnosis, and treatment of cancer, particularly within the Chinese population.
  1. Clinical Oncology:
    The journal emphasizes clinical research, particularly the efficacy and safety of novel therapies, clinical trials, and treatment protocols for various cancers, including gastric, lung, and colorectal cancers.
  2. Molecular and Genetic Studies:
    Research on the molecular mechanisms underlying cancer progression, genetic susceptibility, and tumor markers is a core focus, contributing to personalized medicine and targeted therapies.
  3. Immunotherapy and Immune Microenvironment:
    There is a strong emphasis on studies related to cancer immunotherapy, immune evasion, and the tumor microenvironment, reflecting the growing importance of immunological approaches in cancer treatment.
  4. Epidemiology and Risk Factors:
    The journal publishes epidemiological studies that investigate cancer prevalence, risk factors, and screening strategies, particularly in the context of the Chinese population.
  5. Surgical Techniques and Innovations:
    Research on advancements in surgical methods, including minimally invasive techniques and their outcomes in cancer treatment, is a significant aspect of the journal's scope.
  6. Guidelines and Consensus Statements:
    The journal frequently features updates and discussions on clinical guidelines, ensuring that practitioners are informed about the latest standards in cancer care.
Recent publications in the Chinese Journal of Cancer Research highlight several emerging themes and trends that reflect the evolving landscape of cancer research and treatment. These trends indicate a shift towards more innovative and integrative approaches to understanding and managing cancer.
  1. Integration of Genomics and Precision Medicine:
    There is a growing emphasis on genomic studies and precision medicine, indicating a trend towards personalized treatment strategies based on individual genetic profiles.
  2. Research on Minimal Residual Disease (MRD):
    Emerging studies on the detection and significance of minimal residual disease in various cancers suggest a trend towards improving treatment monitoring and outcomes.
  3. Focus on Microbiome and Cancer Interactions:
    Increasing interest in the role of the microbiome in cancer progression and treatment response reflects a broader understanding of the factors influencing cancer biology.
  4. Innovative Surgical Techniques:
    A trend towards exploring and validating novel surgical techniques, particularly minimally invasive approaches, showcases the journal's commitment to advancing surgical oncology.
  5. Patient-Centric Studies and Quality of Life Assessments:
    There is a notable increase in studies focusing on patient-reported outcomes, symptom management, and quality of life in cancer patients, highlighting a shift towards more holistic cancer care.

Declining or Waning

While the journal continues to cover a wide range of cancer-related topics, some areas appear to be diminishing in frequency or focus. This may reflect shifting priorities in cancer research or changes in clinical practice.
  1. Traditional Chemotherapy Studies:
    There is a noticeable decline in publications focused solely on traditional chemotherapy regimens, as the field shifts towards personalized and targeted therapies.
  2. Radiotherapy Alone Without Combination Approaches:
    Research on radiotherapy as a standalone treatment has decreased, with a growing preference for studies that explore combined modalities, including immunotherapy.
  3. Basic Science Research:
    The journal has shown a waning interest in basic science research unrelated to clinical applications, as more emphasis is placed on translational and clinical studies that have direct implications for patient care.

Similar Journals

Journal of Bone Oncology

Connecting Knowledge for Better Bone Oncology Outcomes
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.

CELLULAR ONCOLOGY

Pioneering Open Access Discoveries in Cellular Oncology
Publisher: SPRINGERISSN: 2211-3428Frequency: 6 issues/year

CELLULAR ONCOLOGY is an esteemed open access journal published by SPRINGER since 2004, specializing in the dynamic field of oncological research. With its ISSN 2211-3428 and E-ISSN 2211-3436, this journal plays a pivotal role in disseminating cutting-edge findings and innovative methodologies that address cancer at the cellular level. The journal has consistently achieved high-impact recognition, currently holding a Q2 rating in Cancer Research and Q1 rankings in Medicine (miscellaneous), Molecular Medicine, and Oncology as of 2023. Furthermore, it ranks 56th in oncology medicine and 48th in cancer research according to Scopus, placing it firmly within the top echelons of its field. Published in the Netherlands, with an aim to connect scientists, clinicians, and practitioners worldwide, CELLULAR ONCOLOGY fosters a collaborative environment for researchers to share insights, enhance understanding, and advance treatments. The journal’s open access model ensures that ground-breaking research is freely available, facilitating greater visibility and impact within the scientific community and beyond.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Transforming cancer research into clinical solutions.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

CANCER INVESTIGATION

Advancing cancer research, one investigation at a time.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Thoracic Cancer

Transforming insights into impactful treatments.
Publisher: WILEYISSN: 1759-7706Frequency: 24 issues/year

Thoracic Cancer is a distinguished open-access journal published by WILEY, dedicated to advancing the field of thoracic oncology. Since its establishment in 2010, the journal has emerged as a crucial platform for the dissemination of innovative research and clinical studies relating to lung cancer and other thoracic malignancies. With a commendable impact reflected in its 2023 Q2 rankings in the categories of Medicine (Miscellaneous), Oncology, and Pulmonary and Respiratory Medicine, the journal features high-quality articles that are vital for researchers, clinicians, and students aspiring to enhance their understanding of thoracic cancers. Operating out of Australia, Thoracic Cancer has embraced a commitment to open access since 2015, ensuring that vital research is readily available to a global audience. The journal's rigorous peer-review process and emphasis on novel findings make it an indispensable resource for professionals seeking to stay at the forefront of this rapidly evolving field.

Journal of the National Cancer Center

Transforming Hematology and Oncology Through Innovation.
Publisher: ELSEVIERISSN: 2667-0054Frequency: 4 issues/year

Journal of the National Cancer Center, published by Elsevier, serves as a pivotal platform in the fields of Cancer Research, Hematology, and Oncology. With an ISSN of 2667-0054, this esteemed journal is recognized for its exceptional quality, achieving a Q1 ranking in all categories as of 2023. Its impressive Scopus rankings place it among the top journals in its field, notably holding rank #11 in Medicine - Hematology and rank #36 in Medicine - Oncology. Addressed from Amsterdam, Netherlands, the journal aims to disseminate cutting-edge research and innovative findings that advance the understanding and treatment of cancer, bridging gaps between laboratory discoveries and clinical applications. Although it follows a subscription model, the journal's commitment to accessibility ensures that valuable knowledge reaches healthcare professionals and researchers globally. By fostering collaboration and facilitating knowledge exchange, the Journal of the National Cancer Center is indispensable for those dedicated to combating cancer and enhancing patient care.

CANCER IMMUNOLOGY IMMUNOTHERAPY

Empowering Cancer Research through Immunological Discoveries
Publisher: SPRINGERISSN: 0340-7004Frequency: 12 issues/year

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Molecular and Clinical Oncology

Connecting researchers to revolutionize cancer treatment.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Cancer Communications

Transforming Cancer Research into Actionable Knowledge
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

Cancers

Advancing cancer research for a healthier tomorrow.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.